Company intelligence / Profile preview

C3J Therapeutics

Marina del Rey, California, United Statesarmatapharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Prior to its merger, C3J developed novel bacteriophage therapies targeting antibiotic-resistant bacterial infections. The company advanced several candidates into clinical development focused on selective treatment of bacterial and fungal diseases. After merging with AmpliPhi Biosciences in May 2019, the combined entity became Armata Pharmaceuticals, which continues the phage therapy pipeline.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage therapeuticsTargeted antimicrobialsVaccines
Industry: Biotech

Drug pipeline

1 asset

C16G2

Phase 1

Indications: Bacterial infections

Partnerships

AmpliPhi Biosciences (merger partner)

Beyond the preview

Go deeper on C3J Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C3J Therapeutics.

Explore the full profile